MARKET

AKBA

AKBA

Akebia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.070
+0.190
+6.60%
Pre Market: 3.110 +0.04 +1.30% 06:43 11/24 EST
OPEN
2.920
PREV CLOSE
2.880
HIGH
3.180
LOW
2.880
VOLUME
415
TURNOVER
--
52 WEEK HIGH
13.71
52 WEEK LOW
2.090
MARKET CAP
443.73M
P/E (TTM)
-1.0348
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500
PR Newswire · 5d ago
Q3 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and selling.
Benzinga · 6d ago
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design, Baseline Characteristics Published In Peer-Reviewed Medical Journal
Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal CAMBRIDGE, Mass., Nov. 16,
Benzinga · 11/16 13:31
Baupost takes new stakes in Pershing Square Tontine, Micro Technology
Seth Klarman's Baupost fund takes new positions in Bill Ackman's Pershing Square Tontine (PSTH) with 17.5M shares and Micron Technology (MU) with 5.22M shares, according to its latest 13F filing.Exits
Seekingalpha · 11/14 00:57
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates
It's shaping up to be a tough period for Akebia Therapeutics, Inc. (NASDAQ:AKBA), which a week ago released some...
Simply Wall St. · 11/07 12:18
Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/05 14:35
Akebia Therapeutics Q3 EPS $(0.42) Misses $(0.17) Estimate, Sales $60.00M Miss $84.90M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.17) by 147.06 percent. This is a 8.7 percent increase over losses of $(0.46) per share
Benzinga · 11/05 13:09
Akebia EPS misses by $0.19, misses on revenue
Akebia (AKBA): Q3 GAAP EPS of -$0.42 misses by $0.19.Revenue of $59.99M (-34.8% Y/Y) misses by $24.91M.Shares -8.56% PM.Press Release
Seekingalpha · 11/05 13:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKBA. Analyze the recent business situations of Akebia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKBA stock price target is 6.71 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 268
Institutional Holdings: 104.42M
% Owned: 72.25%
Shares Outstanding: 144.54M
TypeInstitutionsShares
Increased
66
23.41M
New
79
-24.35M
Decreased
42
8.88M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
Adrian Adams
President/Chief Executive Officer/Director
John Butler
Chief Financial Officer/Senior Vice President/Treasurer
David Spellman
Chief Operating Officer/Senior Vice President
Michel Dahan
Senior Vice President/Secretary
Nicole Hadas
Senior Vice President
Steven Burke
Senior Vice President
Dell Faulkingham
Independent Director
Mark Enyedy
Independent Director
Steven Gilman
Independent Director
Maxine Gowen
Independent Director
Michael Heffernan
Independent Director
Michael Rogers
Independent Director
Cynthia Smith
Independent Director
Myles Wolf
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKBA
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.